Experimental CF drug trial halted early – what we know

NCT ID NCT02649751

First seen Dec 12, 2025 · Last updated Apr 28, 2026 · Updated 15 times

Summary

This study tested a drug called (R)-Roscovitine in adults with cystic fibrosis who have a specific genetic mutation and a chronic lung infection. The goal was to see if increasing doses of the drug are safe. The trial was planned for 36 participants but was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CH Lyon Sud

    Lyon, 69495, France

  • CHR - Hôpital Calmette

    Lille, 59037, France

  • CHU Nantes

    Nantes, 44093, France

  • CHU de Bordeaux - Hôpital Haut-Lévêque

    Pessac, France, 33604, France

  • CHU de Nice - Hôpital Pasteur

    Nice, France, 06001, France

  • Centre Hospitalier Bretagne Atlantique

    Vannes, France, 56017, France

  • Centre de Perharidy

    Roscoff, 29684, France

  • Centre de Ressources et de Compétences de la mucoviscidose

    Reims, France, 51100, France

  • Hôpital Arnaud de Villeneuve

    Montpellier, 34295, France

  • Hôpital Cochin

    Paris, 75014, France

  • Hôpital Larrey

    Toulouse, 30030, France

Conditions

Explore the condition pages connected to this study.